Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks. On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today. One company to watch right now is Merck KGaA (MKKGY). MKKGY is currently sporting a Zacks Rank #1 (Strong Buy), as well as an A grade for Value. Investors will also notice that MKKGY has a PEG ratio of 1.85. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. MKKGY's PEG compares to its industry's average PEG of 1.99. Over the past 52 weeks, MKKGY's PEG has been as high as 2.31 and as low as 1.40, with a median of 2.01. Finally, investors will want to recognize that MKKGY has a P/CF ratio of 6.30. This data point considers a firm's operating cash flow and is frequently used to find companies that are undervalued when considering their solid cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 12.68. MKKGY's P/CF has been as high as 17.18 and as low as 5.95, with a median of 7.25, all within the past year. USANA Health Sciences (USNA) may be another strong Medical - Drugs stock to add to your shortlist. USNA is a Zacks Rank of #2 (Buy) stock with a Value grade of A. USANA Health Sciences is trading at a forward earnings multiple of 10.36 at the moment, with a PEG ratio of 0.86. This compares to its industry's average P/E of 42.68 and average PEG ratio of 1.99. Over the last 12 months, USNA's P/E has been as high as 17.00, as low as 7.83, with a median of 11.26, and its PEG ratio has been as high as 1.42, as low as 0.65, with a median of 0.94. Additionally, USANA Health Sciences has a P/B ratio of 1.11 while its industry's price-to-book ratio sits at 1.63. For USNA, this valuation metric has been as high as 1.72, as low as 0.83, with a median of 1.22 over the past year. Story Continues These are only a few of the key metrics included in Merck KGaA and USANA Health Sciences strong Value grade, but they help show that the stocks are likely undervalued right now. When factoring in the strength of its earnings outlook, MKKGY and USNA look like an impressive value stock at the moment. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Merck KGaA (MKKGY):Free Stock Analysis Report USANA Health Sciences, Inc. (USNA):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
Should Value Investors Buy Merck KGaA (MKKGY) Stock?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...